UAE approves Fondayo obesity pills that provide needle-free weight loss / Photo: File
In a major shift in healthcare, the UAE has approved Vandayo (orforgliprone), a once-daily oral obesity pill developed by Eli Lilly. The decision taken by the Emirates Pharmaceutical Corporation places the country among the first countries in the world to offer a needle-free alternative to injectable weight loss treatments.This approval comes as obesity is increasingly linked to serious long-term conditions, including type 2 diabetes, cardiovascular disease, and some types of cancer. The comfort of the Foundayo is what makes it stand out. Unlike injectable GLP-1 medications, it is taken as a simple daily pill and does not require strict timing between meals or water intake, making adherence easier for patients.
Obesity pills in the UAE are provided without a needle Weight loss
Despite the growing hype, Fondayo is not intended for regular or cosmetic use.
It will only be available on prescription and under strict medical supervision. Doctors across the UAE are expected to follow clear eligibility guidelines before recommending the drug.Patients typically qualify if they have a body mass index (BMI) of 30 or higher, which falls under clinical obesity, or a BMI higher than 27 with related health conditions. These include metabolic diseases, lifestyle diseases such as diabetes, high blood pressure, high cholesterol, sleep apnea, and joint stress conditions.
Before starting treatment, patients will undergo detailed medical evaluations. These include blood tests, metabolic screening, and a complete review of medical history. Specialists such as endocrinologists and internal medicine experts will play a central role in determining whether a drug is appropriate, ensuring that its use remains targeted and medically justified.
How do Fundayo weight loss pills work?
Fondayo belongs to a class of medications known as GLP-1 receptor agonists, which mimic the body’s natural hormones that regulate appetite and blood sugar levels.
In practice, the drug works by helping patients feel full earlier, reducing hunger cues, and lowering overall calorie intake without imposing strict dietary restrictions.Clinical trials have shown strong and consistent results. Patients taking the highest doses recorded an average weight loss of up to 12.4%, while some studies reported a loss of about 12 kilograms over a period of 72 weeks. Beyond weight loss, early results also indicate improvements in cholesterol levels, blood pressure and markers associated with heart disease risk, suggesting broader metabolic benefits.At the same time, doctors warn of the possibility of side effects, especially during the early stages of treatment. Some patients have reported nausea, mild digestive discomfort, and gastrointestinal problems, especially when dosage levels are increased. These effects were generally manageable but highlighted the importance of medical supervision throughout the treatment process.
When will it be available in the UAE?
The pills are expected to be available in UAE pharmacies from May 2026, but access will remain controlled through prescription channels.
Health experts are clear that fundaday is not a shortcut or a one-time solution. Instead, it is designed as part of a long-term treatment plan.In many cases, patients may need to continue taking the medication for long periods, sometimes for life, depending on their condition. Doctors confirm that stopping the medication without maintaining lifestyle changes such as following a balanced diet and exercising regularly may lead to weight regain.
Medication works best when combined with sustainable behavioral changes rather than replacing them.There are also obvious medical exceptions. This medication is not recommended for pregnant or breastfeeding women, and may not be suitable for individuals with certain types of thyroid cancer, endocrine disorders, or severe gastrointestinal or kidney disease. These limitations reinforce the need for careful examination before starting treatment.
The expected price of Fondadio in the UAE
While the official price of Foundayo in the UAE has not yet been confirmed, initial estimates suggest that it could be placed within the same range as existing GLP-1 treatments. Injectable alternatives currently available in the UAE often cost between AED 800 and AED 1,500 per month, depending on the dosage and brand.Industry experts expect Foundayo to be priced competitively within this category, although its oral form could influence final pricing depending on demand and insurance coverage.
Another key factor is whether insurance companies in the UAE classify the drug as primary obesity treatment or elective treatment, which can significantly impact the costs to patients.Affordability will likely play a critical role in adoption. While the convenience of taking a daily pill is expected to attract strong demand, long-term use means that pricing and insurance support will ultimately determine access to the treatment.
UAE authorities emphasize safety checks
Regulators in the UAE have made it clear that the approval of Fundayo is a controlled medical step, not a mass-market weight loss solution. The Emirates Pharmaceutical Corporation said that the drug was approved only after a detailed scientific review of its safety, effectiveness, and performance of clinical trials, and was placed as part of the country’s broader strategy to address the increasing rates of obesity.In its official statement, the authority stressed that this step reflects the UAE’s commitment to providing advanced treatments to patients while maintaining high regulatory standards. Dr. Fatima Al Kaabi, Director General of the Authority, indicated that treating obesity remains a national priority because it is linked to more than 200 diseases, including diabetes, high blood pressure, and cancer. She added that the approval represents a shift toward more patient-friendly treatments.Medical experts have also noted safety considerations associated with medications in the GLP-1 receptor agonist class. Clinical data show that the treatment can cause mild to moderate gastrointestinal side effects such as nausea and vomiting, especially in the early stages or at higher doses.Regulators also stress that the pill is not a stand-alone treatment. It is designed for long-term use as part of a structured obesity management plan that includes lifestyle changes such as diet and physical activity. By combining strict prescription controls with continuous monitoring, the UAE authorities aim to ensure that innovation in treatment does not come at the expense of patient safety while expanding access to effective weight management solutions.[Note: The information provided in this article is for educational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional before starting any new medication or treatment and before changing your diet or supplement regimen.]
